Compare · JNJ vs SER
JNJ vs SER
Side-by-side comparison of Johnson & Johnson (JNJ) and Serina Therapeutics Inc. (SER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and SER operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $538.04B, about 19820.5x SER ($27.1M).
- Over the past year, JNJ is up 43.8% and SER is down 69.9% - JNJ leads by 113.7 points.
- Both names hit the wire about 11 times in the past 4 weeks.
- JNJ has more recent analyst coverage (25 ratings vs 1 for SER).
- Company
- Johnson & Johnson
- Serina Therapeutics Inc.
- Price
- $223.50-0.77%
- $1.82-2.15%
- Market cap
- $538.04B
- $27.1M
- 1M return
- -2.80%
- +0.00%
- 1Y return
- +43.82%
- -69.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2018
- News (4w)
- 11
- 11
- Recent ratings
- 25
- 1
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target
- Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Latest SER
- Chief Executive Officer Ledger Steven A was granted 10,100 shares (SEC Form 4)
- SEC Form 4 filed by SVP, CMC & Formulation Tenjarla Srini
- SEC Form 4 filed by Chief Executive Officer Ledger Steven A
- SEC Form 4 filed by Chief Financial Officer Curhan Gregory S
- SEC Form 4 filed by Chief Scientific Officer Moreadith Randall
- Director Wilson Karen J bought $37,000 worth of shares (20,000 units at $1.85) (SEC Form 4)
- Director Marshall Richard Peter bought $20,102 worth of shares (12,183 units at $1.65) (SEC Form 4)
- SEC Form S-3 filed by Serina Therapeutics Inc.
- Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
- Serina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits